Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krech

Showing results (391-400 of 470) with videos related to

Pageof 47
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 2, 2023
High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian CancerSören Weidemann, Natalia Gorbokon, Maximilian Lennartz, et al.
Pathology, Research and Practice|November 9, 2024
PGP9.5 expression in human tumors: A tissue microarray study on 13,920 tumors from 120 different tumor entitiesSekander Scherzai, Maximilian Lennartz, Frank Jacobsen, et al.
The Prostate|September 21, 2017
High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancerChristoph Burdelski, Rami Shihada, Andrea Hinsch, et al.
Human Pathology|May 13, 2022
Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathologyViktor Reiswich, Gonca Akdeniz, Maximilian Lennartz, et al.
BMC Cancer|December 18, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancerP Lebok, V Kopperschmidt, M Kluth, et al.
Schweizerische Medizinische Wochenschrift|August 25, 1973
[Clinical immunological tests]S Barandun, R Bütler, H Carmann, et al.
Oncotarget|January 10, 2018
Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancerMartina Kluth, Simon Jung, Omar Habib, et al.
Diagnostics (Basel, Switzerland)|October 27, 2022
Analysis of More than 16,000 Human Tumor and Normal Tissues Identifies Uroplakin 3B as a Useful Diagnostic Marker for Mesothelioma and Normal Mesothelial CellsMaximilian Lennartz, Dennis Atug, Sebastian Dwertmann Rico, et al.
International Urology and Nephrology|April 2, 2021
Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancerKatharina Möller, Christoph Fraune, Niclas C Blessin, et al.
Virchows Archiv : an International Journal of Pathology|October 8, 2024
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entitiesKatharina Möller, Tayyaba Gulzar, Maximilian Lennartz, et al.
Pageof 47

Showing results (391-400 of 470) with videos related to

Sort By:
Pageof 47
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 2, 2023
High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian CancerSören Weidemann, Natalia Gorbokon, Maximilian Lennartz, et al.
Pathology, Research and Practice|November 9, 2024
PGP9.5 expression in human tumors: A tissue microarray study on 13,920 tumors from 120 different tumor entitiesSekander Scherzai, Maximilian Lennartz, Frank Jacobsen, et al.
The Prostate|September 21, 2017
High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancerChristoph Burdelski, Rami Shihada, Andrea Hinsch, et al.
Human Pathology|May 13, 2022
Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathologyViktor Reiswich, Gonca Akdeniz, Maximilian Lennartz, et al.
BMC Cancer|December 18, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancerP Lebok, V Kopperschmidt, M Kluth, et al.
Schweizerische Medizinische Wochenschrift|August 25, 1973
[Clinical immunological tests]S Barandun, R Bütler, H Carmann, et al.
Oncotarget|January 10, 2018
Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancerMartina Kluth, Simon Jung, Omar Habib, et al.
Diagnostics (Basel, Switzerland)|October 27, 2022
Analysis of More than 16,000 Human Tumor and Normal Tissues Identifies Uroplakin 3B as a Useful Diagnostic Marker for Mesothelioma and Normal Mesothelial CellsMaximilian Lennartz, Dennis Atug, Sebastian Dwertmann Rico, et al.
International Urology and Nephrology|April 2, 2021
Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancerKatharina Möller, Christoph Fraune, Niclas C Blessin, et al.
Virchows Archiv : an International Journal of Pathology|October 8, 2024
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entitiesKatharina Möller, Tayyaba Gulzar, Maximilian Lennartz, et al.
Pageof 47